http://www.immunetolerance.org/public Latest News en http://www.immunetolerance.org/news/2008/12/itn%E2%80%99s-access-trial-lupus-nephritis-enrolls-first-patient <p> <!--[if gte mso 9]><xml> Normal 0 false false false EN-US X-NONE X-NONE </xml><![endif]--><!--[if gte mso 9]><xml> </xml><![endif]--> <!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-f<p><a href="http://www.immunetolerance.org/news/2008/12/itn%E2%80%99s-access-trial-lupus-nephritis-enrolls-first-patient">read more</a></p> General-News Mon, 29 Dec 2008 16:43:27 -0800 itn_admin 519 at http://www.immunetolerance.org http://www.immunetolerance.org/news/2008/11/welcome-our-new-look <p>Normal<br /> 0<br /> false<br /> false<br /> false<br /> EN-US<br /> X-NONE<br /> X-NONE<br /> MicrosoftInternetExplorer4</p> <p>/* Style Definitions */<br /> table.MsoNormalTable<br /> {mso-style-name:"Table Normal";<br /> mso-tstyle-rowband-size:0;<br /> mso-tstyle-colband-size:0;<br /> mso-style-noshow:yes;<br /> mso-style-priority:99;<br /> mso-style-qformat:yes;<br /> mso-style-parent:"";<br /> mso-padding-alt:0in 5.4pt 0in 5.4pt;<br /> mso-para-margin-top:0in;<br /> mso-para-margin-right:0in;<br /> mso-para-margin-bottom:6.0pt;<br /> mso-para-margin-left:0in;</p> <p><a href="http://www.immunetolerance.org/news/2008/11/welcome-our-new-look">read more</a></p> General-News Thu, 20 Nov 2008 14:07:52 -0800 itn_admin 515 at http://www.immunetolerance.org http://www.immunetolerance.org/news/2008/09/results-itn-phase-i-study-ctla4ig-multiple-sclerosis-published-neurology <p> A phase I study of costimulatory blocking agent CTLA4Ig shows that the treatment appears safe for use in multiple sclerosis and that it can induce favorable immunologic changes. Results from the ITN-led study were published in the September 16, 2008 issue of the peer-reviewed journal Neurology. </p><p><a href="http://www.immunetolerance.org/news/2008/09/results-itn-phase-i-study-ctla4ig-multiple-sclerosis-published-neurology">read more</a></p> General-News Thu, 18 Sep 2008 10:26:31 -0700 itn_admin 338 at http://www.immunetolerance.org